Lower-intensity chemo for fragile pancreatic cancer patients
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 trial compares a standard gemcitabine approach versus a reduced-dose combination chemotherapy for people with pancreatic cancer that can’t be removed by surgery. It aims to find a treatment that works while being safer for “fragile” patients who can’t tolerate full-dose chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older
- Your diagnosis is pancreatic adenocarcinoma confirmed by pathology or a lab test
- Your pancreatic cancer can’t be removed by surgery (locally advanced or metastatic)
- You’re considered too unwell for full-dose combination chemotherapy, but you can take gemcitabine (or reduced-dose combination chemo)
- You have enough blood and organ function (including neutrophils and platelets; bilirubin not too high; kidney function eGFR above 50) and any prior chemo side effects are mostly resolved (less than grade 2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a chemotherapy drug (nab-paclitaxel) combined with other treatments for people with pancreatic cancer. The goal is to see if this combination helps control the cancer or prevents it from coming back after surgery.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, as the first treatment for pancreatic cancer that has spread. The goal is to shrink tumors and improve survival.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for pancreatic cancer that hasn't spread. It aims to see if the combination can shrink tumors and improve survival with manageable side effects.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.